Mavacamten Gets Breakthrough Therapy Status for Obstructive Hypertrophic Cardiomyopathy
The designation is supported by results from the phase 3 EXPLORER-HCM trial that evaluated mavacamten in 251 adult patients with symptomatic, obstructive HCM.
CHF and Arrhythmias
High Prevalence of Americans Have Conditions Linked to Severe COVID-19
Median prevalence of any underlying medical condition 47.2% for residents in all 50 states, DC.
Spironolactone Use Associated With Reduced Prostate Cancer Risk
Men who had ever used spironolactone had decreased odds of prostate cancer compared with never-users, according to a study.
Dapagliflozin Fast-Tracked for Heart Failure Following Acute MI
The FDA has granted Fast Track designation to dapagliflozin (Farxiga; AstraZeneca) to reduce the risk of hospitalization for heart failure or cardiovascular (CV) death in adults following an acute myocardial infarction.
Vericiguat Gets Priority Review for Heart Failure With Reduced Ejection Fraction
The FDA has accepted for Priority Review the New Drug Application for vericiguat to reduce the risk of cardiovascular death and heart failure hospitalization following a worsening heart failure event in patients with symptomatic chronic heart failure with reduced ejection fraction.
Sacubitril/Valsartan Under Review for Heart Failure With Preserved Ejection Fraction
The FDA has accepted for review the supplemental New Drug Application (sNDA) for sacubitril/valsartan (Entresto; Novartis) in the treatment of heart failure with preserved ejection fraction.
Daily Coffee May Lower Risk for Developing Arrhythmia
Each additional cup tied to further decrease in arrhythmia risk.
CVD, Non-CVD Mortality Increased With Azithromycin Use
Cardiovascular death risk increased within five days of azithromycin exposure, but not at six to 10 days.
Physician Sued After Patient Develops Cardiomyopathy From Prescribed Medication
This month we look at a case where the jury ultimately decided for the defendant physician who was sued by a former patient after she developed cardiomyopathy from a medication prescribed by the physician.
Disease-Modifying Drug Regimen May Offer Benefit in Heart Failure
Lower risk for cardiovascular death or hospital admission seen in HF with reduced ejection fraction.
